Intrexon Corporation (NYSE:XON) shares gapped up prior to trading on Thursday . The stock had previously closed at $12.37, but opened at $12.65. Intrexon Corporation shares last traded at $13.62, with a volume of 2971409 shares changing hands.

Several research analysts have recently issued reports on the company. Bank of America Corporation lowered their price objective on Intrexon Corporation from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, November 10th. Stifel Nicolaus upped their price objective on Intrexon Corporation from $39.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Northland Securities reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Intrexon Corporation in a research note on Friday, November 10th. BidaskClub cut Intrexon Corporation from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Finally, JMP Securities reiterated an “outperform” rating and issued a $42.00 target price on shares of Intrexon Corporation in a report on Thursday, October 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $38.50.

The company has a quick ratio of 1.85, a current ratio of 2.05 and a debt-to-equity ratio of 0.01.

In other Intrexon Corporation news, Director Robert B. Shapiro purchased 2,850 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were purchased at an average cost of $17.50 per share, for a total transaction of $49,875.00. Following the acquisition, the director now owns 43,157 shares of the company’s stock, valued at $755,247.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 55.10% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of XON. UBS Asset Management Americas Inc. boosted its holdings in shares of Intrexon Corporation by 16.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 33,333 shares of the biotechnology company’s stock worth $661,000 after buying an additional 4,773 shares in the last quarter. Teachers Advisors LLC lifted its holdings in shares of Intrexon Corporation by 6.8% in the 1st quarter. Teachers Advisors LLC now owns 53,606 shares of the biotechnology company’s stock worth $1,062,000 after purchasing an additional 3,434 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Intrexon Corporation by 102.5% in the 1st quarter. Legal & General Group Plc now owns 18,450 shares of the biotechnology company’s stock worth $365,000 after purchasing an additional 9,340 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Intrexon Corporation by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock worth $84,954,000 after purchasing an additional 226,090 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Intrexon Corporation by 3.5% in the 1st quarter. Geode Capital Management LLC now owns 429,532 shares of the biotechnology company’s stock worth $8,513,000 after purchasing an additional 14,674 shares in the last quarter. Hedge funds and other institutional investors own 77.28% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/11/16/intrexon-corporation-xon-shares-gap-up-to-12-65.html.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.